Pediatric Diabetes Therapeutic Market Size, Share, Trends, & Industry Analysis Report By Type (Type 1, Type 2), By Therapy, By Route of Administration, By Application, By Distribution Channel, and By Region – Market Forecast, 2025–2034

The pediatric diabetes therapeutics market size is expected to reach USD 34.60 Billion by 2034, according to a new study by Polaris Market Research. The report “Pediatric Diabetes Therapeutic Market Size, Share, Trends, & Industry Analysis Report By Type (Type 1, Type 2), By Therapy, By Route of Administration, By Application, By Distribution Channel, and By Region – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Pediatric diabetes therapeutics include insulin therapies, oral antidiabetic drugs, GLP-1 receptor agonists and digital glucose monitoring technologies designed for children and adolescents diagnosed with type 1 and type 2 diabetes. The market is witnessing significant transformation through increased adoption of digital therapeutics, integrated insulin delivery systems, and real-time glucose monitoring platforms.

Market growth is primarily driven by the rising incidence of type 1 diabetes among children, growing diagnosis of early-onset type 2 diabetes and increasing integration of remote monitoring and digital therapeutic platforms. Growing advancements in pediatric-specific insulin delivery systems and expanding regulatory approvals for non-insulin therapies are contributing to treatment accessibility and market expansion across developed and emerging regions.

Pediatric Diabetes Therapeutic Market Report Highlights

Based on type, the type 1 segment accounted for largest share in 2024, due to high prevalence and the requirement for lifelong insulin therapy in pediatric populations.

In terms of therapy, the insulin therapy segment dominated the market in 2024. This is driven by its key role in pediatric diabetes care and growing adoption of smart & digitally integrated delivery systems.

Based on route of administration, the parenteral administration segment held the largest market share in 2024 due to its widespread adoption of insulin injections and smart delivery systems in clinical and home settings.

Based on application, the insulin segment dominated the market in 2024, as it remains the primary treatment for pediatric type 1 diabetes and advanced type 2 cases.

In terms of distribution channel, the hospitals segment dominated the market in 2024. This is fueled by high diagnosis volume and access to advanced therapies.

North America accounted for the majority share in the global pediatric diabetes therapeutic market in 2024, fueled by fueled by structured pediatric endocrinology care and early adoption of digital diabetes management technologies.

Asia Pacific is expected to grow significantly during the forecast period, fueled by increasing childhood diabetes cases and government healthcare investments.

A few global key market players include Novo Nordisk A/S, Sanofi, Eli Lilly and Company, Medtronic plc, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Dexcom Inc., Insulet Corporation, Tandem Diabetes Care Inc., Ascensia Diabetes Care Holdings AG, Glenmark Pharmaceuticals Ltd., and Biocon Limited.

Polaris Market Research has segmented the market report on the basis of type, therapy, route of administration, application, distribution channel, and region:

By Type Outlook (Revenue, USD Billion, 2020–2034)

Type 1

Type 2

By Therapy Outlook (Revenue, USD Billion, 2020–2034)

Drug Therapy

Biguanide

Sodium-glucose co-transporter 2 (SGLT2) inhibitors

Insulin Therapy

Rapid-acting Insulin

Short-acting Insulin

Intermediate-acting Insulin

Long-acting Insulin

By Route of Administration Outlook (Revenue, USD Billion, 2020–2034)

Oral Administration

Nasal Administration

Parenteral Administration

Subcutaneous

Intramuscular

Intravenous

By Application Outlook (Revenue, USD Billion, 2020–2034)

Insulin

GLP-1 Receptor Agonists

Biguanide

SGLT2 Inhibitors

Other Application

By Distribution Channel Outlook (Revenue, USD Billion, 2020–2034)

Hospitals

Specialty Clinics

Retail Pharmacies

Drug Stores

By Regional Outlook (Revenue, USD Billion, 2020–2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America Show more